for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Catalyst Biosciences Inc

CBIO.OQ

Latest Trade

5.69USD

Change

-0.03(-0.52%)

Volume

22,460

Today's Range

5.64

 - 

5.76

52 Week Range

3.44

 - 

8.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Assenagon Asset Management S.A. Reports 6.39% Passive Stake In Catalyst Biosciences Inc

June 19 (Reuters) - Catalyst Biosciences Inc <CBIO.O>::ASSENAGON ASSET MANAGEMENT S.A. REPORTS 6.39% PASSIVE STAKE IN CATALYST BIOSCIENCES INC AS OF JUNE 17 - SEC FILING.

Catalyst Biosciences Announces Pricing Of Public Offering Of Common Stock

June 18 (Reuters) - Catalyst Biosciences Inc <CBIO.O>::CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 4.62 MILLION COMMON SHARES PRICED AT $6.50PER SHARE.

Catalyst Biosciences Announces Proposed Public Offering Of Common Stock

Catalyst Biosciences Inc <CBIO.O>::CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.

Catalyst Biosciences Completes Marzaa Pharmacokinetic & Pharmacodynamic Study

June 10 (Reuters) - Catalyst Biosciences Inc <CBIO.O>::CATALYST BIOSCIENCES COMPLETES MARZAA PHARMACOKINETIC & PHARMACODYNAMIC STUDY.CATALYST BIOSCIENCES - PHASE 1 MAA-102 STUDY RESULTS SUPPORT USE OF SQ MARZAA TO TREAT EPISODIC BLEEDING.CATALYST BIOSCIENCES - ON TRACK TO ENROLL FIRST PATIENT IN ITS PHASE 3 REGISTRATION TRIAL EVALUATING EFFICACY OF SQ MARZAA IN 2020.

Catalyst Biosciences Reports Q1 Loss Per Share $0.28

May 11 (Reuters) - Catalyst Biosciences Inc <CBIO.O>::CATALYST BIOSCIENCES REPORTS FIRST QUARTER 2020 OPERATING & FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.Q1 LOSS PER SHARE $0.28.DALCA PHASE 2B STUDY COMPLETED, FINAL DATA TO BE PRESENTED IN Q2.

Catalyst Biosciences Reports Qtrly Loss Per Share $1.23

Feb 20 (Reuters) - Catalyst Biosciences Inc <CBIO.O>::CATALYST BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2019 OPERATING & FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.CATALYST BIOSCIENCES INC - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS, AS OF DECEMBER 31, 2019 WERE $76.9 MILLION.CATALYST BIOSCIENCES INC QTRLY LOSS PER SHARE $1.23.

Catalyst Biosciences Announces Pricing Of Public Offering Of Common Stock

Feb 13 (Reuters) - Catalyst Biosciences Inc <CBIO.O>::CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.CATALYST BIOSCIENCES - PRICED UNDERWRITTEN PUBLIC OFFERING OF 4.6 MILLION SHARES OF COMMON STOCK AT $6.50/SHARE.

Catalyst Biosciences Announces Proposed Public Offering Of Common Stock

Feb 12 (Reuters) - Catalyst Biosciences Inc <CBIO.O>::CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.

Catalyst Biosciences Announces Addition Of Geoffrey Shiu Fei Ling And Sharon Tetlow To Board

Jan 17 (Reuters) - Catalyst Biosciences Inc <CBIO.O>::CATALYST BIOSCIENCES ANNOUNCES ADDITION OF GEOFFREY SHIU FEI LING, M.D. AND SHARON TETLOW TO BOARD OF DIRECTORS.CATALYST BIOSCIENCES INC - TETLOW IS MANAGING PARTNER AND FOUNDER OF POTRERO HILL ADVISORS.CATALYST BIOSCIENCES INC - ENTERED INTO AN AGREEMENT WITH JDS1, LLC.CATALYST BIOSCIENCES INC - JDS1, LLC WILL VOTE ITS SHARES IN FAVOR OF EACH OF CO'S NOMINEES AT 2020 ANNUAL MEETING.CATALYST BIOSCIENCES INC - AS PART OF AGREEMENT, JDS1, LLC WILL ABIDE BY CUSTOMARY STANDSTILL PROVISIONS AND VOTING COMMITMENTS.CATALYST BIOSCIENCES INC - JEFF HIMAWAN, JOHN RICHARD WILL NOT STAND FOR REELECTION AT 2020 ANNUAL MEETING.

Catalyst Biosciences Announces Global License And Collaboration Agreement To Develop Pegylated CB 2782 For The Treatment Of Dry Age-Related Macular Degeneration

Dec 19 (Reuters) - Catalyst Biosciences Inc <CBIO.O>::CATALYST BIOSCIENCES ANNOUNCES GLOBAL LICENSE AND COLLABORATION AGREEMENT TO DEVELOP PEGYLATED CB 2782 FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION.CATALYST BIOSCIENCES INC - ENTERED INTO A GLOBAL LICENSE AND COLLABORATION AGREEMENT WITH BIOGEN.CATALYST BIOSCIENCES INC - BIOGEN WILL RECEIVE AN EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP AND COMMERCIALIZE CB 2782-PEG.CATALYST - BIOGEN WILL RECEIVE EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP & COMMERCIALIZE CO'S OTHER ANTI-C3 PROTEASES FOR POTENTIAL TREATMENT OF DRY AMD.CATALYST BIOSCIENCES INC - CATALYST WILL RECEIVE A $15 MILLION UPFRONT PAYMENT AND IS ELIGIBLE TO RECEIVE UP TO $340 MILLION IN MILESTONE PAYMENTS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up